Recently, the Shankar Lab in CERES highlighted the extent of this problem and a new solution for rapid diagnosis of CNS lymphoma. In a new publication in the journal Blood https://pubmed.ncbi.nlm.nih.gov/33735913/, lead author Mihir Gupta led the characterization of a new strategy for CNS lymphoma diagnosis based on early detection of canonical MYD88 mutations. At CERES, we believe this strategy will lead to earlier and more rapid diagnosis of CSF lymphoma. In a recent case, a patient presented to Mass General with enhancement and FLAIR signal changes in the midbrain, thalamus, and basal ganglia. On a research protocol, the patient was found to be MYD88 positive just 12 hours after presentation, confirming the presence of this key mutation signature of CNS lymphoma. The CERES team, led by Dr. Shankar in collaboration with the MGH Pathology Dept is developing a CLIA certified version of this assay.